Recurrent Malignant Testicular Germ Cell Tumor Completed Phase 1 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0028803 (Recurrent Malignant Testicular Germ Cell Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004074Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuTreatment